BYNFEZIA PEN (Octreotide Acetate) Patent Expiration, LOE Window & CMS Spending

BYNFEZIA PEN (Octreotide Acetate) by Sun Pharmaceutical: FDA Orange Book core substance LOE 2038-05-15 (last listed 2041-12-29), 0 AB generics, $0 2024 CMS Part D & Medicaid spend, and 1 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorSun Pharmaceutical
FDA Application & PathwayN213224 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2038-05-15
Last Listed Patent or Exclusivity Date2041-12-29
Orange Book Patents (*PED Extensions)13 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)1 WAC filings (max 20.6% 2-yr change)